Malaria vaccines: recent advances and new horizons
The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …
accounting for the majority of malaria, and P. vivax being a second important cause …
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …
infection of human malaria has proved challenging, and no candidate vaccine has affected …
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine
RA Seder, LJ Chang, ME Enama, KL Zephir… - Science, 2013 - science.org
Consistent, high-level, vaccine-induced protection against human malaria has only been
achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites …
achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites …
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
L Swadling, S Capone, RD Antrobus, A Brown… - Science translational …, 2014 - science.org
A protective vaccine against hepatitis C virus (HCV) remains an unmet clinical need. HCV
infects millions of people worldwide and is a leading cause of liver cirrhosis and …
infects millions of people worldwide and is a leading cause of liver cirrhosis and …
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
DA Stanley, AN Honko, C Asiedu, JC Trefry… - Nature medicine, 2014 - nature.com
Ebolavirus disease causes high mortality, and the current outbreak has spread unabated
through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus …
through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus …
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
KA Collins, R Snaith, MG Cottingham, SC Gilbert… - Scientific reports, 2017 - nature.com
The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
K Ewer, T Rampling, N Venkatraman… - … England Journal of …, 2016 - Mass Medical Soc
Background The West African outbreak of Ebola virus disease that peaked in 2014 has
caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority …
caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority …
The march toward malaria vaccines
SL Hoffman, J Vekemans, TL Richie, PE Duffy - Vaccine, 2015 - Elsevier
In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …
Viral vectors as vaccine platforms: from immunogenicity to impact
Highlights•Safety and potency of simian adenovirus vectors is now well established, most
recently in infants.•Viral vectored vaccines are effective against malaria and Ebola in field …
recently in infants.•Viral vectored vaccines are effective against malaria and Ebola in field …